Published in Int J Exp Pathol on March 06, 2014
Global data on visual impairment in the year 2002. Bull World Health Organ (2004) 28.05
The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 14.96
Glutathione reductase. Methods Enzymol (1985) 4.80
Regulation of glutathione synthesis. Mol Aspects Med (2008) 3.40
Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol (1981) 2.85
The sorbitol pathway and the complications of diabetes. N Engl J Med (1973) 2.51
Redox regulation in the lens. Prog Retin Eye Res (2003) 2.11
Glutathione-related enzymes and the eye. Curr Eye Res (2006) 1.67
THE ESTIMATION OF THE OXIDIZED AND REDUCED FORMS OF THE NICOTINAMIDE NUCLEOTIDES. Biochem J (1965) 1.38
Aldose reductase in diabetic complications of the eye. Metabolism (1979) 1.15
Role of nonenzymatic glycosylation in the development of the sequelae of diabetes mellitus. Metabolism (1979) 1.09
Glutathione synthesis and turnover in the human erythrocyte: alignment of a model based on detailed enzyme kinetics with experimental data. J Biol Chem (2010) 1.08
Regulation of reductive processes by glutathione. Biochem Pharmacol (1986) 1.08
Bovine lens aldehyde reductase (aldose reductase). Purification, kinetics and mechanism. Biochem J (1984) 1.06
Hormonal regulation of glutathione efflux. J Biol Chem (1990) 0.98
Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol Cell Endocrinol (2007) 0.98
Induction and maintenance of differentiation of rat lens epithelium by FGF-2, insulin and IGF-1. Exp Eye Res (1998) 0.95
Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol (2007) 0.95
Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate. Diabetes Obes Metab (2000) 0.95
From a dull enzyme to something else: facts and perspectives regarding aldose reductase. Curr Med Chem (2008) 0.93
Role of growth factors in the development of diabetic complications. Horm Res (2000) 0.90
Expression patterns for glucose transporters GLUT1 and GLUT3 in the normal rat lens and in models of diabetic cataract. Invest Ophthalmol Vis Sci (2003) 0.89
Combination of glycemic and oxidative stress in lens: implications in augmentation of cataract formation in diabetes. Free Radic Res (2005) 0.89
Effect of growth factors on proliferation and expression of growth factor receptors in a human lens epithelial cell line. J Cataract Refract Surg (2006) 0.88
Aldose reductase and the etiology of diabetic cataracts. Curr Top Eye Res (1980) 0.87
The effect of an aldose reductase inhibitor (Sorbinil) on the level of metabolites in lenses of diabetic rats. Diabetes (1983) 0.87
Protective effect of ascorbate against oxidative stress in the mouse lens. Biochim Biophys Acta (2004) 0.86
Aldehyde reductase from human tissues. Methods Enzymol (1982) 0.85
Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res (2001) 0.85
Somatostatin analogues as therapeutics in retinal disease. Pharmacol Ther (2009) 0.84
Effect of aldose reductase inhibitor (sorbinil) on integration of polyol pathway, pentose phosphate pathway, and glycolytic route in diabetic rat lens. Diabetes (1986) 0.83
Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin. J Neurochem (2012) 0.83
Lens polyol dehydrogenase. Exp Eye Res (1973) 0.82
Insulin and IGF-I affect the protein composition of the lens fibre cell with possible consequences for cataract. Exp Eye Res (2000) 0.80
Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol (2002) 0.80
Effect of experimental diabetes on glycolytic intermediates and regulation of phosphofructokinase in rat lens. Biochem Biophys Res Commun (1980) 0.80
Effects of somatostatin analogues on retinal angiogenesis in a mouse model of oxygen-induced retinopathy: involvement of the somatostatin receptor subtype 2. Invest Ophthalmol Vis Sci (2009) 0.80
The effect of a somatostatin analogue (SMS 201-995, Sandostatin) on the concentration of phosphoribosyl pyrophosphate and the activity of the pentose phosphate pathway in the early renal hypertrophy of experimental diabetes in the rat. Biochem Med Metab Biol (1988) 0.79
Modelling cortical cataractogenesis. 13. Early effects on lens ATP/ADP and glutathione in the streptozotocin rat model of the diabetic cataract. Exp Eye Res (1993) 0.79
Purification and kinetics of bovine kidney cortex glutathione reductase. Protein Pept Lett (2010) 0.78
Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes. Int J Exp Pathol (2012) 0.78
Differential effects of somatostatin and angiopeptin on cell proliferation. Br J Pharmacol (1998) 0.77
Insulin-like growth factor-1 (IGF-1) specifically binds to bovine lens epithelial cells and increases the number of fibronectin receptor sites. Curr Eye Res (1994) 0.77
Antioxidant status in an in vitro model for hyperglycemic lens cataract formation: effect of aldose reductase inhibitor statil. Biochem Med Metab Biol (1988) 0.77
Purification and properties of human cataractous lens glyceraldehyde-3-phosphate dehydrogenase. Curr Eye Res (1985) 0.77
Octreotide inhibits growth factor-induced and basal proliferation of lens epithelial cells in vitro. J Cataract Refract Surg (2005) 0.77
Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev Ophthalmol (2007) 0.76
Kinetic analysis of rat liver sorbitol dehydrogenase. Int J Biochem (1983) 0.76
Lens metabolism and cellular effects of aldose reductase. Diabet Med (1985) 0.76
Insulin and IGF-I effects on the synthesis of aldose reductase in rat lens cells. Exp Eye Res (1999) 0.76
The effect of phenazine methosulphate on intermediary pathways of glucose metabolism in the lens at different glycaemic levels. Exp Eye Res (1995) 0.76
Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14
Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology (2003) 3.59
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27
Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81
Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol (2009) 2.79
Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol (2005) 2.75
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology (2009) 2.39
Whey and casein labeled with L-[1-13C]leucine and muscle protein synthesis: effect of resistance exercise and protein ingestion. Am J Physiol Endocrinol Metab (2010) 1.82
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev (2004) 1.74
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology (2014) 1.73
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes (2002) 1.69
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens (2009) 1.61
Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab (2006) 1.61
Adiponectin and lipoprotein particle size. Diabetes Care (2009) 1.60
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care (2006) 1.52
Effects of five different alcoholic drinks on patients with Crohn's disease. Scand J Gastroenterol (2007) 1.51
Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.49
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart (2012) 1.47
Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology (2012) 1.44
Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer (2010) 1.40
Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. Biomaterials (2006) 1.38
Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol (2009) 1.36
Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care (2005) 1.35
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol (2006) 1.34
Assessment of early diabetic renal changes with hyperpolarized [1-(13) C]pyruvate. Diabetes Metab Res Rev (2013) 1.34
Cardiovascular disease and insulin-like growth factor I. Circulation (2002) 1.30
Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev (2007) 1.27
Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes (2012) 1.27
The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol (2009) 1.18
Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol (2012) 1.17
Dlk1/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone. Endocrinology (2007) 1.16
Ghrelin and its relationship to growth hormones during normal pregnancy. Clin Endocrinol (Oxf) (2005) 1.15
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol (2010) 1.15
Effect of estrogen on tendon collagen synthesis, tendon structural characteristics, and biomechanical properties in postmenopausal women. J Appl Physiol (1985) (2008) 1.13
Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab (2007) 1.12
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab (2008) 1.12
Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol (2007) 1.12
Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J (2008) 1.11
Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes (2005) 1.10
Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin. Crit Care (2009) 1.10
Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med (2006) 1.09
Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2004) 1.06
Complement activation and diabetic vascular complications. Clin Chim Acta (2005) 1.06
Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology (2012) 1.05
Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care (2008) 1.04
Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J (2010) 1.04
Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol (2006) 1.03
Expression of insulin-like growth factor I, insulin-like growth factor binding proteins, and collagen mRNA in mechanically loaded plantaris tendon. J Appl Physiol (1985) (2006) 1.01
Sex-discordant associations with adiponectin levels and lipid profiles in children. Diabetes (2006) 1.00
Serum adiponectin in elderly men does not correlate with fracture risk. J Clin Endocrinol Metab (2008) 0.99
Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J Clin Endocrinol Metab (2002) 0.98
The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women. Am J Hypertens (2009) 0.98
Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration. Clin Endocrinol (Oxf) (2006) 0.98
A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant (2005) 0.96
Adiponectin and risk of congestive heart failure. JAMA (2006) 0.96
Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol (2006) 0.95
Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol (2011) 0.95
Relationship between periodontitis and diabetes: lessons from rodent studies. J Periodontol (2007) 0.95
Acute growth hormone administration induces antidiuretic and antinatriuretic effects and increases phosphorylation of NKCC2. Am J Physiol Renal Physiol (2006) 0.95
Human placental growth hormone, insulin-like growth factor I and -II, and insulin requirements during pregnancy in type 1 diabetes. J Clin Endocrinol Metab (2003) 0.95
Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol (2006) 0.94
Left ventricular volume measurement in mice by conductance catheter: evaluation and optimization of calibration. Am J Physiol Heart Circ Physiol (2007) 0.94
Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy. Diabetes (2003) 0.93
Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol (2013) 0.93
GH and IGF1 levels are positively associated with musculotendinous collagen expression: experiments in acromegalic and GH deficiency patients. Eur J Endocrinol (2010) 0.93
Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) (2007) 0.93
Periodontitis is associated with aggravation of prediabetes in Zucker fatty rats. J Periodontol (2007) 0.93
No effect of menstrual cycle on myofibrillar and connective tissue protein synthesis in contracting skeletal muscle. Am J Physiol Endocrinol Metab (2005) 0.93
Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol (2003) 0.92
Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocrinol (2006) 0.92
Ethinyl oestradiol administration in women suppresses synthesis of collagen in tendon in response to exercise. J Physiol (2008) 0.92
Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. J Clin Endocrinol Metab (2004) 0.92
Simultaneous detection of porcine cytokines by multiplex analysis: development of magnetic bioplex assay. Vet Immunol Immunopathol (2009) 0.91
Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol (2009) 0.91
Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol Dial Transplant (2004) 0.91
Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2011) 0.91
Periodontitis deteriorates metabolic control in type 2 diabetic Goto-Kakizaki rats. J Periodontol (2006) 0.91
Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol (2006) 0.91
Exercise-dependent IGF-I, IGFBPs, and type I collagen changes in human peritendinous connective tissue determined by microdialysis. J Appl Physiol (1985) (2006) 0.90
Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem (2002) 0.90
Body composition and common carotid artery remodeling in a healthy population. J Clin Endocrinol Metab (2008) 0.90
Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol (2011) 0.90
Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol (2009) 0.90
Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention. J Invasive Cardiol (2009) 0.90
Effects of ischemic pre- and postconditioning on HIF-1α, VEGF and TGF-β expression after warm ischemia and reperfusion in the rat liver. Comp Hepatol (2011) 0.90
Adiponectin and left ventricular structure and function in healthy adults. J Clin Endocrinol Metab (2008) 0.89
Physical capacity influences the response of insulin-like growth factor and its binding proteins to training. J Appl Physiol (1985) (2002) 0.89
Mannan-binding lectin in diabetic kidney disease: the impact of mouse genetics in a type 1 diabetes model. Exp Diabetes Res (2012) 0.88
Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia (2013) 0.88
Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail (2009) 0.88
Ischemic pre- and postconditioning has pronounced effects on gene expression profiles in the rat liver after ischemia/reperfusion. Am J Physiol Gastrointest Liver Physiol (2012) 0.88